About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01311713

Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors

Study identifier: NCT01311713
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

CEP-9722 (Cephalon)

Eligibility:

  • Open to males or females who’s disease has progressed following at least 1 prior standard chemotherapy regimen.
    Part II: Documented deficiency in DNA Repair Pathway (BRCA1/2) or prostate, breast, or gastric cancer

Type of study:

Phase I/II

Treatment:

  • Patients receive CEP-9722 administered daily or twice-daily for six 28-day cycles.

Study site:

Michigan

Henry Ford Health System Protocol Review Committee
Detroit, Michigan, United States, 48202
Contact: 1-877-237-4879 (Cephalon)

Missouri

Washington University School of Medicine
St. Louis, Missouri, United States, 63110
Contact: 1-877-237-4879 (Cephalon)

Page updated 11/30/11


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org